Acorda Therapeutics Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Acorda Therapeutics Inc.

ACOR 0.880

-13.8%

Apr 10 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Arthur Radley	8/3/2010 2:49:33 PM
	Read Replies (1) of 120

Acorda 2Q loss narrows on Ampyra sales 10:50 am ET 08/03/2010 - Associated Press Online Biotechnology company Acorda Therapeutics Inc. said Tuesday its second-quarter loss narrowed on a boost in sales of the multiple sclerosis drug Ampyra. The company lost $6.8 million, or 18 cents per share, compared with a loss of $23.3 million, or 62 cents per share, during the same period a year prior. Revenue surged to $42.8 million from $12.6 million, mainly on sales of Ampyra. The drug was approved by federal regulators in January. The drug aims to improve walking in patients with multiple sclerosis, an often disabling disease that affects the brain and nervous system. Analysts polled by Thomson Reuters expected a loss of 46 cents on $29 million in revenue. Shares rose $1.84, or 5.6 percent, to $35 in morning trading.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next